BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Subcutaneous RoActemra tocilizumab: Phase III data

A double-blind, Japanese Phase III trial in 346 patients showed that 162 mg subcutaneous RoActemra every 2 weeks met the primary endpoint of non-inferiority to 8 mg/kg IV RoActemra every 3 weeks in ACR20 response rate at 24 weeks. The safety of the subcutaneous formulation was consistent with...

Read the full 220 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >